InvestorsHub Logo
Followers 13
Posts 724
Boards Moderated 0
Alias Born 11/17/2011

Re: None

Friday, 05/30/2014 11:23:00 PM

Friday, May 30, 2014 11:23:00 PM

Post# of 403035
United States Patent Application 20140046057
Kind Code A1
Cohen; Benjamin M. ; et al. February 13, 2014

Assignee: Celgene Corporation
Summit
NJ

[0565] In one embodiment, the second active agent is HDAC inhibitor. In one embodiment, the HDAC inhibitor is vorinostat, romidepsin, panobinostat, valproic acid, belinostat, mocetinostat, abexinostat, entinostat, SB939, resminostat, givinostat, CUDC-101, AR-42, CHR-2845, CHR-3996, 4SC-202, CG200745, ACY-1215, sulforaphane, kevetrin, or trichostatin A.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News